PFIZER INC

Listed Company

PFECIK 0000078003NYSELarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$62.58B

Net Income

$7.77B

Total Assets

$208.00B

Equity

$86.48B

Shares Out

5.70B

Op. Cash Flow

$11.70B

+ 13F Filer

PFE$24.31−3.72% · past yearDBEQ Basic

Daily closing prices

Business

Pfizer Inc. is a research-based, global biopharmaceutical company that discovers, develops, manufactures, markets, sells and distributes medicines and vaccines worldwide. The company offers innovative biopharmaceutical products across primary care (vaccines, cardiovascular, migraine), specialty care (inflammation & immunology, rare disease), oncology (ADCs, small molecules, bispecifics), and hospital & biosimilars portfolios. Pfizer operates through a single reportable segment, Biopharma, with commercial divisions serving U.S. and international markets, alongside a contract development and manufacturing organization (PC1) supplying specialty active pharmaceutical ingredients.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Alliance revenues	9,266	8,388	7,582	8,537	7,652
Total revenues	62,579	63,627	59,553	101,175	81,288
Cost of sales	16,067	17,851	24,954	34,344	30,821
Selling, informational and administrative expenses	13,794	14,730	14,771	13,677	12,703
Research and development expenses	10,437	10,822	10,679	11,428	10,360
Acquired in-process research and development expenses	1,613	108	194	953	3,469
Amortization of intangible assets	4,874	5,286	4,733	3,609	3,700
Restructuring charges and certain acquisition-related costs	1,550	2,419	2,943	1,375	802
Other (income)/deductionsnet	6,724	4,388	222	1,062	−4,878
Income from continuing operations before provision/(benefit) for taxes on income	7,520	8,023	1,058	34,729	24,311
Provision/(benefit) for taxes on income	−266	−28	−1,100	3,300	1,852
Income from continuing operations	7,787	8,051	2,172	31,401	22,459
Discontinued operationsnet of tax	25	11	−15	6	−434
Net income before allocation to noncontrolling interests	7,812	8,062	2,158	31,407	22,025
Less: Net income attributable to noncontrolling interests	41	31	39	35	45
Net income attributable to Pfizer Inc. common shareholders	7,771	8,031	2,119	31,372	21,979
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	1.37	1.42	0.38	5.59	4
Discontinued operationsnet of tax (in dollars per share)	0	0	0	0	−0.08
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	1.37	1.42	0.38	5.59	3.92
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	1.36	1.41	0.37	5.47	3.93
Discontinued operationsnet of tax (in dollars per share)	0	0	0	0	−0.08
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	1.36	1.41	0.37	5.47	3.85
Weighted-average sharesbasic (in shares)	5,683	5,664	5,643	5,608	5,601
Weighted-average sharesdiluted (in shares)	5,713	5,700	5,709	5,733	5,708

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	1,142	1,043	2,853	416	1,944
Short-term investments	12,454	19,434	9,837	22,316	29,125
Trade accounts receivable, net of allowance for doubtful accounts: 2025$427; 2024$438	11,874	11,463	11,566	10,952	11,479
Inventories	10,654	10,851	10,189	8,981	9,059
Current tax assets	3,967	3,314	3,978	3,577	4,266
Other current assets	2,808	4,253	4,911	5,017	3,820
Total current assets	42,898	50,358	43,333	51,259	59,693
Long-term investments	1,621	2,228	3,731	4,036	5,054
Property, plant and equipment, net	19,317	18,393	18,940	16,274	14,882
Identifiable intangible assets, net	53,731	55,411	64,900	43,370	25,146
Goodwill	71,264	68,527	67,783	51,375	49,208
Noncurrent deferred tax assets and other noncurrent tax assets	9,699	8,662	3,706	6,693	3,341
Other noncurrent assets	9,631	9,817	12,471	13,163	7,679
Total assets	208,000	213,000	227,000	197,000	181,000
Short-term borrowings, including current portion of long-term debt: 2025$2,997; 2024$3,747	3,154	6,946	10,350	2,945	2,241
Trade accounts payable	5,240	5,633	6,710	6,809	5,578
Dividends payable	2,445	2,437	2,372	2,303	2,249
Income taxes payable	3,103	2,910	2,349	1,587	1,266
Accrued compensation and related items	3,610	3,838	2,776	3,407	3,332
Deferred revenues	784	1,511	2,700	2,520	3,067
Other current liabilities	18,648	19,720	20,537	22,568	24,939
Total current liabilities	36,984	42,995	47,794	42,138	42,671
Long-term debt	62,000	57,000	62,000	33,000	36,000
Pension and postretirement benefit obligations	2,041	2,115	2,167	2,250	3,724
Noncurrent deferred tax liabilities	2,401	2,122	640	1,023	349
Other taxes payable	3,591	6,112	8,534	9,812	11,331
Other noncurrent liabilities	14,725	14,150	16,539	13,180	9,743
Total liabilities	121,385	124,899	137,213	101,288	104,013
Commitments and Contingencies	—	—	—	—	—
Common stock, $0.05 par value; 12,000 shares authorized; issued: 20259,621; 20249,593	481	480	478	476	473
Additional paid-in capital	94,469	93,603	92,631	91,802	90,591
Treasury stock, shares at cost: 20253,935; 20243,926	−115,015	−114,763	−114,487	—	—
Retained earnings	114,610	116,725	118,353	125,656	103,394
Accumulated other comprehensive loss	−8,069	−7,842	−7,961	−8,304	−5,897
Total Pfizer Inc. shareholders equity	86,476	88,203	89,014	95,661	77,201
Equity attributable to noncontrolling interests	299	294	274	256	262
Total equity	86,775	88,497	89,288	95,916	77,462
Total liabilities and equity	208,160	213,396	226,501	197,205	181,476

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	6,592	7,013	6,290	5,064	5,191
Asset write-offs and impairments	5,270	4,242	3,408	550	276
Deferred taxes	−2,133	−2,102	−3,442	−3,764	−4,293
Share-based compensation expense	799	877	525	872	1,182
Benefit plan contributions in excess of expense/income	−786	−12	−787	−1,158	−3,123
Inventory write-offs and related charges associated with COVID-19 products	0	0	6,199	1,183	0
Other adjustments, net	−470	−2,260	−3,492	758	−1,573
Trade accounts receivable	−263	−109	347	261	−3,811
Inventories	561	−854	−1,169	−591	−1,125
Other assets	1,289	3,380	−663	−4,506	−1,057
Trade accounts payable	−469	−1,023	−300	1,191	1,242
Other liabilities	−3,667	−3,115	595	−1,449	18,721
Other tax accounts, net	−2,805	−1,345	−982	−545	−1,166
Net cash provided by/(used in) operating activities	11,704	12,744	8,700	29,267	32,580
Purchases of property, plant and equipment	−2,629	−2,909	−3,907	−3,236	−2,711
Purchases of short-term investments	−14,356	−10,133	−30,974	−36,384	−38,457
Proceeds from redemptions/sales of short-term investments	17,959	4,128	39,264	44,821	27,447
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less	−2,675	3,136	5,174	−483	−8,088
Purchases of long-term investments	−294	−180	−204	−1,913	−1,068
Proceeds from redemptions/sales of long-term investments	1,095	1,570	1,979	641	649
Proceeds from partial sales of investment in Haleon	6,311	7,040	0	0	—
Acquisitions of businesses, net of cash acquired	−6,927	0	−43,430	−22,997	0
Other investing activities, net	165	2	−179	−192	−305
Net cash provided by/(used in) investing activities	−1,351	2,652	−32,278	−15,783	−22,546
Proceeds from short-term borrowings	0	8,907	4,525	3,891	0
Payments on short-term borrowings	−2,199	−11,226	−3	−3,887	0
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less	−796	−2,590	3,161	−222	−96
Proceeds from issuance of long-term debt	9,678	0	30,831	0	997
Payments on long-term debt	−6,757	−2,250	−2,569	−3,298	−2,004
Cash dividends paid	−9,771	−9,512	−9,247	−8,983	−8,729
Other financing activities, net	−458	−469	−631	−335	16
Net cash provided by/(used in) financing activities	−10,304	−17,140	26,066	−14,834	−9,816
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents	41	−66	−40	−165	−59
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents	91	−1,810	2,448	−1,515	159
Income taxes	4,688	3,605	3,147	7,867	7,427
Interest paid	2,739	3,227	2,215	1,442	1,467
Interest rate hedges	140	178	134	54	−2
Right-of-use assets obtained in exchange for lease liabilities	288	283	614	752	1,943

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Holdings (13F)

Portfolio as of 2025-12-31 · 21 positions

Reported AUM

$236.45M

Holdings

Top sector

$236.45M

Top sectors

Sector	Value	% of portfolio
Uncategorized	$236.45M	100.0%

Top holdings

Issuer	Ticker	Shares	Value	%
ORIC PHARMACEUTICALS INC	—	5.38M	$43.98M	18.6%
ARVINAS INC	—	3.46M	$41.01M	17.3%
CELCUITY INC	—	349.4K	$34.85M	14.7%
WAVE LIFE SCIENCES LTD	—	1.88M	$31.88M	13.5%
ALLOGENE THERAPEUTICS INC	—	22.03M	$30.18M	12.8%
ZURA BIO LTD	—	2.97M	$15.56M	6.6%
CARIBOU BIOSCIENCES INC	—	4.69M	$7.46M	3.1%
PYXIS ONCOLOGY INC	—	5.95M	$6.84M	2.9%
CARDIFF ONCOLOGY INC	—	2.41M	$6.78M	2.9%
BIOHAVEN LTD	—	505.6K	$5.71M	2.4%

Frequently asked questions

What is PFIZER INC's CIK number?

PFIZER INC's SEC CIK number is 0000078003 (78003). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find PFIZER INC's SEC filings?

All of PFIZER INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did PFIZER INC last report earnings?

PFIZER INC (PFE) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000078003-26-000053). This is PFIZER INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is PFIZER INC's most recent earnings 8-K?

PFIZER INC's latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0000078003-26-000053. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View PFIZER INC's latest earnings 8-K →
Look up any company's CIK number →